Scholarlink

<p>Sickle cell disease (SCD) is characterized by painful vaso-occlusive crises (VOC), which occur due to the adhesion of sickled erythrocytes and leukocytes to the endothelium, leading to vascular obstruction and tissue ischemia. Recurrent VOC increases SCD morbidity, reduces quality of life, and results in frequent hospitalizations. While factors like HbF levels and alpha-thalassemia co-occurrence are known to influence the risk of VOC, the genetic basis of this phenotype remains underexplored. To address this, we conducted a Genome-Wide Association Study (GWAS) to identify genetic predictors of frequent VOC in SCD patients. The study focused on patients with the SS genotype, analyzing those who experienced three or more pain crisis hospitalizations annually. To account for population substructure, the top 10 principal components were included. The GWAS was performed using ENCORE and the Saige Logistic Mixed Model, adjusted for hydroxyurea treatment as a covariate, with a genome-wide significance threshold of 5 × 10<sup>-8</sup>. The study included 125 cases and 1670 controls, revealing 9 significant SNPs. 8 were associated with the CTNNA2 gene (p-value = 7.77 × 10<sup>-9</sup>), and 1 with METTL4 (p-value = 3.39 × 10<sup>-8</sup>). These findings highlight the role of CTNNA2 and METTL4 in VOC hospitalizations, providing insights into the genetic underpinnings of SCD pain.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic modifiers of frequent vaso-occlusive hospitalizations among individuals with sickle cell disease (SCD)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月14日

查看全文
  • Mina Cintho Ozahata,
  • Isabel Gomes,
  • Beatriz A. Oliveira,
  • Miriam Park,
  • Daniela O. W. Rodrigues,
  • Anna Bárbara Carneiro-Proietti,
  • Cláudia Máximo,
  • Allison Ashley-Koch,
  • Marilyn Telen,
  • Shannon Kelly,
  • Brian Custer,
  • Ester Cerdeira Sabino,
  • Carla Luana Dinardo

摘要

Sickle cell disease (SCD) is characterized by painful vaso-occlusive crises (VOC), which occur due to the adhesion of sickled erythrocytes and leukocytes to the endothelium, leading to vascular obstruction and tissue ischemia. Recurrent VOC increases SCD morbidity, reduces quality of life, and results in frequent hospitalizations. While factors like HbF levels and alpha-thalassemia co-occurrence are known to influence the risk of VOC, the genetic basis of this phenotype remains underexplored. To address this, we conducted a Genome-Wide Association Study (GWAS) to identify genetic predictors of frequent VOC in SCD patients. The study focused on patients with the SS genotype, analyzing those who experienced three or more pain crisis hospitalizations annually. To account for population substructure, the top 10 principal components were included. The GWAS was performed using ENCORE and the Saige Logistic Mixed Model, adjusted for hydroxyurea treatment as a covariate, with a genome-wide significance threshold of 5 × 10-8. The study included 125 cases and 1670 controls, revealing 9 significant SNPs. 8 were associated with the CTNNA2 gene (p-value = 7.77 × 10-9), and 1 with METTL4 (p-value = 3.39 × 10-8). These findings highlight the role of CTNNA2 and METTL4 in VOC hospitalizations, providing insights into the genetic underpinnings of SCD pain.